Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target
Shattuck Labs (STTK) has an average rating of buy and mean price target of $15, according to analysts polled by FactSet.
5 stories mentioning STTKUpdated 20d ago
Every FINWIRES story that references STTK, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Shattuck Labs (STTK) has an average rating of buy and mean price target of $15, according to analysts polled by FactSet.
Shattuck Labs (STTK) has an average rating of buy and mean price target of $15, according to analysts polled by FactSet.
Healthcare stocks were steady pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up a slight 0.1%.Tango Therapeutics (TNGX) shares were up more than 45% after the company said initial results from its phase 1/2 trial of vopimetostat in combination with Revolution Medicines' inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer.Eli Lilly (LLY) shares were up more than 2% after the company said additional phase 3 data showed that retatrutide achieved substantial weight loss with "meaningful" improvements in obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes.Shattuck Labs (STTK) said its phase 1 study of SL-325, a treatment for immune-related disease, showed good safety results and consistent drug performance in healthy volunteers. Shattuck Labs stock was up more than 14% premarket.
Shattuck Labs (STTK) has an average rating of buy and mean price target of $12.50, according to analysts polled by FactSet.
Shattuck Labs (STTK) has an average rating of Buy and mean price target of $12, according to analysts polled by FactSet.